Fig. 5

\(\widetilde {\text {IC}}_{50}^{\text {eff}}\) (i.e. IC\(_{50}^{\text {eff}}\) relative to native Bcr-Abl IC\(_{50}^{\text {eff}}\)) for selected mutations towards an asciminib + ATP-pocket TKI combination. Boxes highlighted in red are more sensitive towards mutations than the \(\widetilde {\text {IC}}_{50}^{\text {eff}}\) would suggest (as described in Fig. 1) assuming a 90% inhibition target. Drug names are abbreviated as: imatinib – IM, nilotinib – NI, dasatinib – DA, bosutinib – BO, ponatinib – PO, and asciminib – AS